Globally, an overwhelming percentage of medical decisions are made based on the results of in vitro diagnostics (IVD) testing. The percentage is rising, even more, courtesy the current pandemic, which has spurred the demand for efficienttesting technologies, instruments, reagents, and diagnostics software at unprecedented levels.
In the wake of COVID, the healthcare industry is gradually being pushed towards recognizing the need for fast disease identification and personalized care for patients aided by the advanced use of analytics. Alongside, an increasingly aging global population, the widespread prevalence of chronic diseases fueled by sedentary lifestyles, and an upsurge in occurrences of infectious diseases no less potent than COVID have made even tech innovators sit up and take note.
Becoming increasingly cognizant of these trends, medical device manufacturers are broadening their present IVDtechnology portfolios as well as focusing on establishing new ones. Point-of-care (POC) testing, liquid biopsies, molecular diagnostics, AI, and IoT are some of the technologies driving innovation in the IVD space, apart from genomic research. It is clear that the IVD space is undergoing rapid transformation to keep up with the latest healthcare challenges.
On that note, a distinguished panel of CEOs, CIOs, VCs, and other thought leaders from the industry, along with the editorial board of MedTech Outlook APAC, has selected the leading in vitro diagnostic solution providers looking to offer their expertise to the widest market possible.
In this edition, we present to you MedTech Outlook APAC’s ‘Top 10 Diagnostics Solution Companies – 2021.’